Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAXBiotechnology
+$0.00 today
- Market cap
- $622.71M
- Beta
- -0.53
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$2.59
Volume 1.30M
Average 0.54M
BCAX Other Non-current Assets
Long-term assets not reported separately.
Bicara Therapeutics Inc. Common StockNASDAQ: BCAX
Other Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Other non-current assets rises 4.1% from a year ago
Other non-current assets stood at $6.91M at the end of Q1 FY2026, up 4.1% from a year earlier and up 0.0% from the prior quarter. Over 3 fiscal years it compounded at +85.5% a year.
Context
- Other non-current assets amounted to 1.2% of total assets at the end of Q1 FY2026, down 0.1 pp from a year earlier.
- Other non-current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current assets keeps rising in the next quarterly balance sheet after a +4.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 6.91M USD
- Year-over-year change
- +4.4%
- 3-year CAGR
- +85.5%
| Period | Period end | Other Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.91M | +4.4% |
| FY2024 | 2024-12-31 | 6.62M | +216.0% |
| FY2023 | 2023-12-31 | 2.09M | +93.4% |
| FY2022 | 2022-12-31 | 1.08M | — |
Other Non-current Assets vs competitors
How BCAX compares with its peers on the latest reported figures
- BCAX's Mar 2026 other non-current assets of $6.91M is the highest of the 6 companies compared; the peer median is $297K.
- Its year-over-year change of +4.1% is the highest of 4, against a peer median of -7.7%.
- Other non-current assets amounts to 1.2% of total assets for BCAX, versus a peer median of 0.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
BCAXBicara Therapeutics Inc. Common Stock | Mar 2026 | $6.91M | +4.1% | +85.5% | 1.2% |
| Mar 2026 | $1.38M | -7.7% | +0.2% | 0.6% | |
| Mar 2026 | $568K | +0.0% | +21.1% | 0.3% | |
| Mar 2026 | $297K | -18.9% | -13.5% | 0.1% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | -$3.47M | — | — | 1.7% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding BCAX) | $297K | -7.7% | +0.2% | 0.3% | |
Competitors are the stored peer set for BCAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
Intrinsic Alpha fair value
Locked
Current Price
$9.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.